Lakewood-Amedex Biotherapeutics, Inc. (LABT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Lakewood-Amedex Biotherapeutics, Inc. (LABT) closed at USD 0.63 on 2026-10-14, a change of -99.3 % over the past year, with a market capitalization of USD 1.45M.

Lakewood-Amedex Biotherapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Lakewood-Amedex Biotherapeutics, Inc. key figures

Previous close

USD 0.63 (2026-10-14)

1-year change

-99.3 %

Market cap

USD 1.45M

Enterprise value

USD -3.03M

P/E ratio (trailing)

-0.07

P/E ratio (forward)

n/a

EPS (trailing)

-8.83

EPS (forward)

n/a

PEG ratio

n/a

Price to book

0.31

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.05

Employees

5

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Lakewood-Amedex Biotherapeutics, Inc.

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Lakewood-Amedex Biotherapeutics, Inc. and compare it with other stocks.